Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.62 |
| ▸ | HTR7 | P34969 | 6/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.50 |
| ▸ | HRH1 | P35367 | 1/20 | 0.49 |
| ▸ | HTR6 | P50406 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1243510 | 0.85 | HRH3 (0.46) | HRH3HTR7HTR6 | |
| SCHEMBL2400927 | 0.83 | HRH3 (0.46) | HRH3HTR7 | |
| SCHEMBL1241268 | 0.83 | HRH3 (0.46) | HRH3HTR7 | |
| SCHEMBL19465427 | 0.82 | HRH3 (0.46) | HRH3HTR7 | |
| Water SCHEMBL16161850 | 0.82 | HRH3 (0.46) | HRH3HTR7 | |
| Oxalic Acid SCHEMBL1241171 | 0.80 | HRH3 (0.44) | HRH3HTR7 | |
| SCHEMBL1243667 | 0.79 | HTR7 (0.46) | HTR7HTR6 | |
| SCHEMBL5630601 | 0.78 | HTR7 (0.45) | HRH3HTR7HTR6 | |
| SCHEMBL2437062 | 0.78 | HRH3 (0.56) | HRH3HRH1 | |
| Fumaric Acid SCHEMBL9898673 | 0.77 | TSHR (0.41) | HRH3HTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1753725-B1 | TETRAHYDROISOQUINOLINE SULFONAMIDE DERIVATIVES, THE PREPARATION THEREOF, AND THE USE OF THE SAME IN THERAPEUTICS | SANOFI SA (FR) | 2013-02-27 | — | — | EP | claimed |
| US-8273733-B2 | Tetrahydroisoquinoline sulfonamide derivatives, the preparation thereof, and the use of the same in therapeutics | SANOFI (FR) | 2012-09-25 | — | — | US | claimed |
| US-20110028475-A1 | TETRAHYDROISOQUINOLINE SULFONAMIDE DERIVATIVES, THE PREPARATION THEREOF, AND THE USE OF THE SAME IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2011-02-03 | — | — | US | claimed |
| US-7833999-B2 | Tetrahydroisoquinoline sulfonamide derivatives, the preparation thereof, and the use of the same in therapeutics | SANOFI-AVENTIS (FR) | 2010-11-16 | — | — | US | claimed |
| US-20070105834-A1 | TETRAHYDROISOQUINOLINE SULFONAMIDE DERIVATIVES, THE PREPARATION THEREOF, AND THE USE OF THE SAME IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2007-05-10 | — | — | US | claimed |
| EP-1753725-A1 | TETRAHYDROISOQUINOLINE SULFONAMIDE DERIVATIVES, THE PREPARATION THEREOF, AND THE USE OF THE SAME IN THERAPEUTICS | Sanofi-Aventis (FR) | 2007-02-21 | — | — | EP | claimed |
| WO-2005118547-A1 | TETRAHYDROISOQUINOLINE SULFONAMIDE DERIVATIVES, THE PREPARATION THEREOF, AND THE USE OF THE SAME IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2005-12-15 | — | — | WO | claimed |
| US-8524700-B2 | Tetrahydroisoquinoline sulfonamide derivatives, the preparation thereof, and the use of the same in therapeutics | SANOFI (FR) | 2013-09-03 | — | — | US | disclosed |
| EP-1753725-B1 | TETRAHYDROISOQUINOLINE SULFONAMIDE DERIVATIVES, THE PREPARATION THEREOF, AND THE USE OF THE SAME IN THERAPEUTICS | SANOFI SA (FR) | 2013-02-27 | — | — | EP | disclosed |
| US-20120323003-A1 | TETRAHYDROISOQUINOLINE SULFONAMIDE DERIVATIVES, THE PREPARATION THEREOF, AND THE USE OF THE SAME IN THERAPEUTICS | SANOFI (FR) | 2012-12-20 | — | — | US | disclosed |
| US-8273733-B2 | Tetrahydroisoquinoline sulfonamide derivatives, the preparation thereof, and the use of the same in therapeutics | SANOFI (FR) | 2012-09-25 | — | — | US | disclosed |
| US-20110028475-A1 | TETRAHYDROISOQUINOLINE SULFONAMIDE DERIVATIVES, THE PREPARATION THEREOF, AND THE USE OF THE SAME IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2011-02-03 | — | — | US | disclosed |
| US-7833999-B2 | Tetrahydroisoquinoline sulfonamide derivatives, the preparation thereof, and the use of the same in therapeutics | SANOFI-AVENTIS (FR) | 2010-11-16 | — | — | US | disclosed |
| US-20070105834-A1 | TETRAHYDROISOQUINOLINE SULFONAMIDE DERIVATIVES, THE PREPARATION THEREOF, AND THE USE OF THE SAME IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2007-05-10 | — | — | US | disclosed |
| EP-1753725-A1 | TETRAHYDROISOQUINOLINE SULFONAMIDE DERIVATIVES, THE PREPARATION THEREOF, AND THE USE OF THE SAME IN THERAPEUTICS | Sanofi-Aventis (FR) | 2007-02-21 | — | — | EP | disclosed |
| WO-2005118547-A1 | TETRAHYDROISOQUINOLINE SULFONAMIDE DERIVATIVES, THE PREPARATION THEREOF, AND THE USE OF THE SAME IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2005-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120323003-A1 | TETRAHYDROISOQUINOLINE SULFONAMIDE DERIVATIVES, THE PREPARATION THEREOF, AND THE USE OF THE SAME IN THERAPEUTICS | BACE1, HTR2B, KCNQ2 | HRH3 104/4885HTR7 227/4885L3MBTL1 2395/4885 |
| US-20070105834-A1 | TETRAHYDROISOQUINOLINE SULFONAMIDE DERIVATIVES, THE PREPARATION THEREOF, AND THE USE OF THE SAME IN THERAPEUTICS | BACE1, SLC6A2, KCNQ2 | HRH3 128/4885HTR7 175/4885L3MBTL1 3012/4885 |
| US-20110028475-A1 | TETRAHYDROISOQUINOLINE SULFONAMIDE DERIVATIVES, THE PREPARATION THEREOF, AND THE USE OF THE SAME IN THERAPEUTICS | BACE1, HTR2B, KCNQ2 | HRH3 104/4885HTR7 227/4885L3MBTL1 2395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.